Simulations Plus (NASDAQ:SLP): Navigating Earnings and Legal Challenges Amid Altaris Acquisition
Simulations Plus (NASDAQ:SLP), a leader in modeling and simulation software for the pharmaceutical and biotechnology industries, is on the verge of releasing its third-quarter fiscal 2026 earnings results. Scheduled for July 9, 2026, the company is anticipated to report an earnings per share (EPS) of $0.23 alongside revenues of approximately $20.90 million. These figures are crucial as they come during a transformative period for the company.
Corporate Transition and Acquisition Details
On June 16, 2026, Simulations Plus announced a definitive agreement to be acquired by affiliates of Altaris, LLC, in an all-cash transaction valued at around $375 million. This acquisition is set to provide Simulations Plus stockholders with $18.50 per share in cash, reflecting a 26% premium over the company’s 60-day volume-weighted average price as of June 15, 2026. The deal is expected to close in the fourth quarter of calendar 2026, contingent upon shareholder and regulatory approvals.
However, due to the acquisition, Simulations Plus has opted not to hold earnings calls while the transaction is pending. Investors will have to rely primarily on the earnings press release and related disclosures for the latest updates, which could impact their investment strategies.
Legal Scrutiny and Investor Concerns
Simulations Plus is currently under legal scrutiny from shareholder rights law firms, notably Johnson Fistel, PLLP. The firm is investigating on behalf of investors who may have experienced losses, focusing on whether these losses could be recoverable under federal securities laws following the company’s disclosures. This investigation stems from a significant guidance reduction announced in June 2025, where Simulations Plus reduced its fiscal 2025 revenue guidance from an earlier estimate of $90 million to $93 million to a new range of $76 million to $80 million.
This guidance cut was attributed to budget reductions, project cancellations, and delays from pharmaceutical and biotechnology customers, which subsequently led to a more than 24% drop in share prices. The situation has left many investors cautious about the company’s future performance.
Financial Performance and Impairment Charges
In July 2025, Simulations Plus reported a significant third-quarter fiscal 2025 net loss of $67.3 million, or $3.35 per diluted share, which included a $77.2 million non-cash impairment charge. This impairment was based on a valuation assessment aimed at aligning the book value of its assets with current market conditions. Such drastic measures raised eyebrows among investors and analysts alike.
Furthermore, the company disclosed changes involving its independent registered public accounting firm. Grant Thornton informed the SEC about unresolved matters related to segment reporting and internal controls over financial reporting, which may have contributed to the current legal scrutiny.
Recent Earnings and Future Guidance
In its most recent update, Simulations Plus reported second-quarter fiscal 2026 revenues of $24.3 million, representing an 8% increase year-over-year. The company posted a net income of $4.5 million and diluted EPS of $0.22, with an adjusted diluted EPS of $0.35. Despite these positive indicators, the company revised its fiscal 2026 adjusted diluted EPS guidance downwards to a range of $0.75 to $0.85, a notable decrease from the previous estimate of $1.03 to $1.10, primarily due to expectations of a higher effective tax rate. The revenue guidance remained consistent at $79 million to $82 million.
Current Financial Stability
Despite the challenges, Simulations Plus maintains a relatively strong balance sheet. Recent data indicates a current ratio of 5.47, showcasing substantial short-term liquidity. Additionally, the company’s total debt-to-equity ratio stands at approximately 0.38%, indicating limited leverage and a solid financial footing.
Conclusion and Outlook
As Simulations Plus approaches its earnings release, the focus will not only be on its quarterly performance but also on how investors interpret the company’s operating momentum amid legal scrutiny and the pending Altaris acquisition. The implications of these developments will be critical for stakeholders, as they navigate the complexities of the pharmaceutical modeling and simulation market. Investors will be keeping a close eye on the upcoming announcements, as they could significantly influence the company’s stock trajectory in the coming months.
